Monopar Therapeutics (MNPR) earnings date
Mar 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 21 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | during market hours | 43 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | during market hours | 44 | 8-K |
| Q4 FY2025 | Fri, Mar 27, 2026 | during market hours | 86 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | before open | 43 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | before open | 43 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | before open | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "Monopar expects its current funds to support operations through at least March 31, 2028, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development." exhibit |
| Q3 FY2026 | "The increase is attributed to interest earned on U.S. Treasury securities and commercial paper and to higher bank balances in 2026 due to the net proceeds of approximately $91.9 million from the September 2025 capital raise." exhibit |
| Q3 FY2026 | "Kent is leading the Company’s medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that the Company is on track to complete the NDA submission within the next several weeks; and that Monopar expects its current funds to support operations through at least March 31, 2028." exhibit |
| Q2 FY2026 | "Monopar expects its current funds to support operations through at least December 31, 2027, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development." exhibit |
| Q2 FY2026 | "The increase is attributed to interest earned on U.S. Treasury securities and commercial paper and to higher bank balances in 2026 due to the net proceeds of approximately $91.9 million from the September 2025 capital raise." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MNPR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MNPR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MNPR/"><img src="https://veritasdata.dev/embed/MNPR.svg" alt="MNPR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MNPR/)
Script
<script async src="https://veritasdata.dev/embed/MNPR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MNPR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.